TD Cowen Initiates Coverage On Dyne Therapeutics with Buy Rating

Dyne Therapeutics Inc

Dyne Therapeutics Inc

DYN

0.00

TD Cowen analyst Joseph Thome initiates coverage on Dyne Therapeutics (NASDAQ: DYN) with a Buy rating.